A perspective in Discover Public Health argued that extending artemether–lumefantrine beyond existing practice requires geographically targeted evaluation rather than blanket adoption across African malaria programs. The piece focused on how differences in local delivery conditions, resistance patterns, and program structures can change outcomes from what trial results might suggest. The emphasis on evaluation design matters for implementers because malaria treatment policies are often scaled quickly, and the expected impact can fail if regional context is ignored. The authors’ framing is that policy should follow targeted operational evidence rather than one-size-fits-all decisions. For public health stakeholders and drug-policy decision-makers, the key takeaway is that program heterogeneity can determine whether a regimen’s effectiveness carries over at scale.
Get the Daily Brief